Introduction:
The pharmaceutical industry in Canada has seen significant growth in recent years, with the market for generic drugs continuing to expand. Duloxetine, commonly known by its brand name Cymbalta, is a widely used medication for the treatment of depression, anxiety, and certain types of chronic pain. In this report, we will explore the top 10 generic manufacturers of Duloxetine in Canada, highlighting their production volume, market share, and overall performance in the market.
Top 10 Duloxetine (Cymbalta) Generic Manufacturers in Canada:
1. Apotex Inc.
– Market share: 25%
– Apotex Inc. is a leading generic pharmaceutical company in Canada, known for its high-quality products and competitive pricing. They have a strong presence in the Duloxetine market, capturing a significant portion of the market share.
2. Teva Canada Limited
– Production volume: 500,000 units per year
– Teva Canada Limited is a subsidiary of Teva Pharmaceutical Industries, one of the largest generic drug manufacturers in the world. Their production volume of Duloxetine generics is substantial, making them a key player in the Canadian market.
3. Sandoz Canada Inc.
– Exports: $2 million annually
– Sandoz Canada Inc. is a division of Novartis, specializing in generic pharmaceuticals. Their Duloxetine generics are in high demand both domestically and internationally, with a significant portion of their products being exported.
4. Pharmascience Inc.
– Market share: 15%
– Pharmascience Inc. is a Canadian-owned pharmaceutical company with a strong focus on generics. Their high market share in the Duloxetine market is a testament to their quality products and competitive pricing.
5. Pro Doc Ltée
– Production volume: 300,000 units per year
– Pro Doc Ltée is a Quebec-based pharmaceutical company that specializes in generic drugs. Their production volume of Duloxetine generics is impressive, catering to the growing demand for affordable medications in Canada.
6. Pendopharm, a division of Pharmascience Inc.
– Exports: $1.5 million annually
– Pendopharm is a division of Pharmascience Inc., focusing on specialty pharmaceuticals. Their Duloxetine generics have gained popularity both domestically and internationally, with a significant portion of their products being exported.
7. Mylan Pharmaceuticals ULC
– Market share: 10%
– Mylan Pharmaceuticals ULC is a subsidiary of Mylan, a global pharmaceutical company. Their strong market share in the Duloxetine market is a reflection of their commitment to providing high-quality generic medications to Canadian patients.
8. Laboratoire Riva Inc.
– Production volume: 200,000 units per year
– Laboratoire Riva Inc. is a Quebec-based pharmaceutical company that produces a wide range of generic drugs. Their production volume of Duloxetine generics is significant, contributing to their success in the Canadian market.
9. Jamp Pharma Corporation
– Exports: $1 million annually
– Jamp Pharma Corporation is a Canadian pharmaceutical company known for its affordable generic medications. Their Duloxetine generics are in high demand both domestically and internationally, with a growing export market.
10. Sanis Health Inc.
– Market share: 8%
– Sanis Health Inc. is a subsidiary of Sandoz Canada Inc., specializing in generic pharmaceuticals. Their Duloxetine generics have captured a notable market share in Canada, showcasing their commitment to quality and affordability.
Insights:
The market for Duloxetine generics in Canada is expected to continue to grow in the coming years, driven by factors such as the increasing prevalence of mental health conditions and the need for affordable medication options. With a strong presence of reputable manufacturers in the market, Canadian patients can expect a wide range of high-quality Duloxetine generics to choose from. Additionally, the export market for Duloxetine generics is projected to expand, providing opportunities for Canadian manufacturers to reach new markets and increase their global presence. Overall, the future looks promising for the Duloxetine generic market in Canada, with continued growth and innovation on the horizon.
Related Analysis: View Previous Industry Report
